跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 16,036 条关于
“HUTCHMED (China) Limited”
全部
16,036
临床试验
3,291
药物
240
机构
1,528
资讯
10,977
4年前
HUTCHMED Announces Savolitinib sNDA Accepted in China for NSCLC Treatment
去年
HUTCHMED's ORPATHYS and TAGRISSO Combination Receives Priority Review in China for Lung Cancer
17小时前
Hutchmed Reports Positive Phase III SANOVO Trial Results in Lung Cancer
去年
HUTCHMED's Sovleplenib Shows Promising Long-Term Efficacy in ITP Phase III Trial
去年
HUTCHMED Reports 65% Growth in Oncology Products Revenue, Achieves Profitability in 2024
8个月前
HUTCHMED's Sovleplenib Meets Primary Endpoint in Phase III Trial for Warm Autoimmune Hemolytic Anemia
4年前
China NMPA Accepts NDA for ORPATHYS® and TAGRISSO® Combination in NSCLC with MET Amplification
去年
FDA Approves New Cancer Treatments Amidst Rising Global Cancer Rates
去年
Fruzaqla (Fruquintinib) Launched in Japan by Takeda for Metastatic Colorectal Cancer
2个月前
Analysts Maintain Bullish Stance on HUTCHMED (China) with Buy Ratings and Price Targets Above HK$32
第 1 页,共 1098 页
上一页
下一页